Trials / Completed
CompletedNCT03531229
Single Ascending Dose Study of Lu AF76432 in Healthy Young Men
Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-oral-dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF76432 in Healthy Young Men
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate safety, tolerability and pharmacokinetics of the drug Lu AF76432 given as single oral ascending doses to healthy young men
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo to Lu AF76432 oral solution |
| DRUG | Lu AF76432 | Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s). |
Timeline
- Start date
- 2018-04-17
- Primary completion
- 2019-02-22
- Completion
- 2019-02-22
- First posted
- 2018-05-21
- Last updated
- 2019-04-12
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03531229. Inclusion in this directory is not an endorsement.